Functional Analysis of Estrogen Receptor 1 in Diabetic Wound Healing: A Knockdown Cell-Based and Bioinformatic Study

ABC Sha Qi
BC Qiong Han
D Danmou Xing
CE Long Qian
E Xiang Yu
F Dong Ren
E Huan Wang
ABFG Quan Chen

Corresponding Author: Quan Chen, e-mail: 382326563@qq.com
Source of support: Departmental sources

Background: Diabetic wound (DW) treatment is a serious challenge for clinicians, and the underlying mechanisms of DWs remain elusive. We sought to identify the critical genes in the development of DWs and provide potential targets for DW therapies.

Material/Methods: Datasets of GSE38396 from the Gene Expression Omnibus (GEO) database were reviewed. Pathway analysis was performed using the Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology term analyses were carried out, and Cytoscape software (Cytoscape 3.7.2) was used to construct the protein interaction network. Serum samples from patients with diabetes and control participants were collected, and the expression of estrogen receptor 1 (ESR1) was measured by quantitative reverse-transcription polymerase chain reaction. In addition, the function of ESR1 in human skin fibroblasts was investigated in vitro.

Results: Eight samples were analyzed using the Morpheus online tool, which identified 637 upregulated and 448 downregulated differentially expressed genes. The top 5 KEGG pathways of upregulated differentially expressed genes were associated with sphingolipid metabolism, estrogen signaling, ECM-receptor interaction, MAPK signaling, and PI3K-Akt signaling. The hub genes for DWs were JUN, ESR1, CD44, SMARCA4, MMP2, BMP4, GSK3B, WDR5, PTK2, and PTGS2. JUN, MMP2, and ESR1 were the upregulated hub genes, and ESR1 was found to be consistently enriched in DW patients. Inhibition of ESR1 had a stimulative role in human skin fibroblasts.

Conclusions: ESR1 was identified as a crucial gene in the development of DWs, which suggests potential therapeutic targets for DW healing.

MeSH Keywords: Diabetic Angiopathies • Fibroblasts • Genes, vif

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/928788
Background

It is widely accepted that a diagnosis of diabetes requires a substantial change in dietary habits and can produce overwhelming mental and social stress [1]. In addition, neurovascular lesions, secondary infection, hypoxia, and other harmful factors can cause diabetic wounds (DWs) that are challenging for clinicians to treat. Further, because these lesions are usually incurable, they cause economic and psychological burdens for patients [2]. A large number of studies have focused on the potential mechanisms underlying DW development [3]. For example, a recent study reported that circulating microRNA-20b-5p derived from the serum of patients with diabetes is associated with the deterioration of DWs, thereby providing a new therapeutic target for their treatment [4]. Similarly, a study regarding the therapeutic strategies for diabetic foot ulcers indicated that exosomal microRNA-15a-3p plays a crucial role in regulation of the healing progress through the NOX5/ROS signaling pathway [5]. Although many studies regarding DWs have been carried out, a clear mechanism for their development remains elusive.

Regulatory factors in vivo affect the angiogenesis and the ability of a wound to resist infection. The regeneration of tissue around a wound plays a crucial role in the healing process of DW, and various regulatory genes can directly or indirectly modulate this process. For instance, ubiquitin-conjugating enzyme E2 (UBE2O) derived from salivary exosomes was reported to accelerate wound repair via targeting decapentaplegic homolog 6 (SMAD6) [6]. It was similarly reported that palmitate-TLR4 signaling plays a key regulatory role in DW healing via targeting the histone demethylase (JMJD3) [7]. Therefore, DWs are thought to be related to multiple regulatory genes and caused by gene-environment interactions.

A DNA microarray (also commonly known as DNA chip or biochip) is a collection of microscopic DNA spots attached to a solid surface. Such microarrays have been used to investigate the underlying pathogenic processes in a variety of diseases, and they have become crucial in functional genomic studies [8–10]. This technique has been widely applied to identify significant regulatory genes in diabetic diseases [11]. The differentially expressed genes (DEGs) are assumed to be related to changes in the levels of proteins that have significant functionality in this context and thus to have important regulatory effects in the progression of diabetes-related diseases. Therefore, we sought to identify critical DEGs in the development of DWs by using a comprehensive method based on bioinformatics.

Material and Methods

Gene chip data acquisition

The Gene Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo) repository is a database of high-throughput gene expression data and hybridization arrays, chips, and microarrays. We searched this database for the RNA microarray data comparing people with type 2 diabetes with a normal population. We then downloaded the files.

Identification of DEGs

Morpheus (https://software.broadinstitute.org/morpheus) is an online software for data visualization and analysis. We uploaded reorganized GEO data to this online tool. A heat map produced by Morpheus sorted the DEGs with signal to noise >1 or signal to noise <–1.

Enrichment analyses of Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathways

The online tool Database for Annotation, Visualization, and Integrated Discovery version (DAVID) Bioinformatics Resources 6.8 was used to the biological function of the genes [12,13]. Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed with DAVID.

Protein–protein interaction network construction

Upregulated and downregulated genes were imported into the software STRING (Search Tool for the Retrieval of Interacting Genes, https://string-db.org/), which identified the genes with a combined score of >0.5. (This score is based on the likelihood of interaction, and >0.5 is the default value.) Subsequently, the protein–protein interaction (PPI) network was constructed using Cytoscape software (version 3.7.2) [14]. Next, an analysis of the function enrichment was performed using DAVID, and the DEGs were ranked by degree centrality using the plugin software Centscape 2.2 in Cytoscape. Degree represents the degree to which one node is associated with all other nodes in the network. Closeness represents how close a node is to other nodes in the network. Betweenness is the number of times that a node acts as the shortest bridge between 2 other nodes.

Ethics approval

The present study was approved by the Committees of Ethics in Wuhan Fourth Hospital (Wuhan, Hubei, China; 2019-021-17).
**Figure 1.** The top 60 differentially expressed genes (DEGs) of GSE38396 (30 upregulated and 30 downregulated) are presented in the heat map.
Sample collection from patients and healthy controls

From April 2019 to March 2020, peripheral blood samples from patients with DWs and healthy controls in our hospital (30 non-diabetic patients with foot trauma, and 30 diabetic patients with foot ulcers) were obtained for the subsequent validation of mRNA levels of the upregulated hub genes.

Cell culture and transfection

Human skin fibroblasts (HSFs; FuHeng Biology, Shanghai, China) were cultured in high-glucose Dulbecco’s modified Eagle’s medium (Gibco BRL, Grand Island, NY, USA) with 10% fetal bovine serum. For transfection, Lipofectamine 3000 (ThermoFisher Scientific) was used following the manufacturer’s instructions. Briefly, cells were cultured at 37°C with 5% CO₂ and 95% humidity. For the transfection of mRNA and siRNA oligos steps, constructs from RIBOBIO (Guangzhou) were utilized, and cells were transfected with ESR1 siRNA (RIBOBIO, Guangzhou) at 50 nM.

Quantitative reverse-transcription polymerase chain reaction analyses

The total RNA was obtained from the serum samples. cDNA was then obtained through reverse and transcribe of the purified RNA. GAPDH served as an internal control. Relative miRNA expression levels were normalized to those of the internal control and were calculated according to the $2^{-ΔΔCq}$ approach. The primer sequences were as follows: ESR1, forward, GACAGGGAGCTGGTTCACAT.

Table 1. The upregulated and downregulated differentially expressed genes (DEGs) in biological process.

| Term        | Function                                      | Count | P-value |
|-------------|-----------------------------------------------|-------|---------|
| GO: 0043547 | Positive regulation of GTPase activity       | 32    | 3.0E-4  |
| GO: 0072358 | Cardiovascular system development             | 42    | 4.1E-4  |
| GO: 0072359 | Circulatory system development                | 41    |         |
| GO: 0051345 | Positive regulation of hydrolase activity     | 40    | 8.4E-4  |
| GO: 0007507 | Heart development                              | 26    | 1.1E-3  |

| Term        | Function                                      | Count | P-value |
|-------------|-----------------------------------------------|-------|---------|
| GO: 0008283 | Cell proliferation                            | 70    | 1.4E-6  |
| GO: 0061458 | Reproductive system development               | 26    | 3.2E-6  |
| GO: 0008285 | Negative regulation of cell proliferation     | 32    | 1.8E-5  |
| GO: 0010605 | Negative regulation of macromolecule metabolic process | 77    | 3.7E-5  |

Table 2. The upregulated and downregulated differentially expressed genes (DEGs) in cellular component.

| Term        | Function                                      | Count | P-value |
|-------------|-----------------------------------------------|-------|---------|
| GO: 0031904 | Endosome lumen                                | 6     | 4.8E-4  |
| GO: 0044447 | Axoneme part                                  | 5     | 2.4E-3  |
| GO: 0005788 | Endoplasm reticulum lumen                    | 13    | 6.6E-3  |
| GO: 005775  | Vacuolar lumen                                | 9     | 1.1E-2  |
| GO: 0031906 | Late endosome lumen                           | 3     | 1.3E-2  |

| Term        | Function                                      | Count | P-value |
|-------------|-----------------------------------------------|-------|---------|
| GO: 0005654 | Nucleoplasm                                   | 105   | 2.4E-7  |
| GO: 0044451 | Nucleoplasm part                              | 31    | 8.8E-4  |
| GO: 0005912 | Adherens junction                             | 29    | 1.4E-3  |
| GO: 0070161 | Anchoring junction                            | 29    | 2.0E-3  |
| GO: 0001725 | Stress fiber                                  | 6     | 6.4E-3  |
Table 3. The upregulated and downregulated differentially expressed genes (DEGs) in molecular function.

| Term                        | Function                              | Count | P-value   |
|-----------------------------|---------------------------------------|-------|-----------|
| GO: 0005085                 | Guanyl-nucleotide exchange factor activity | 17    | 3.1E-3    |
| GO: 0098772                 | Molecular function regulator           | 50    | 4.2E-3    |
| GO: 0005088                 | Ras guanyl-nucleotide exchange factor activity | 13    | 8.8E-3    |
| GO: 0052745                 | Inositol phosphate phosphatase activity | 4     | 9.9E-3    |
| GO: 0030170                 | Pyridoxal phosphate binding            | 6     | 1.2E-2    |

**Downregulated**

| Term                        | Function                              | Count | P-value   |
|-----------------------------|---------------------------------------|-------|-----------|
| GO: 0044822                 | Poly(A) RNA binding                    | 50    | 7.8E-6    |
| GO: 000166                  | Nucleotide binding                     | 80    | 3.4E-5    |
| GO: 1901265                 | Nucleoside phosphate binding           | 80    | 3.4E-5    |
| GO: 0036094                 | Small molecule binding                 | 82    | 1.4E-4    |
| GO: 0097367                 | Carbohydrate derivative binding        | 73    | 2.0E-4    |

Table 4. The Kyoto Encyclopedia of Genes and Genomes analysis of upregulated and downregulated differentially expressed genes (DEGs).

| Term                        | Function                              | Count | P-value   |
|-----------------------------|---------------------------------------|-------|-----------|
| hsa00600                    | Sphingolipid metabolism pathway       | 6     | 5.3E-3    |
| hsa04915                    | Estrogen signaling pathway            | 8     | 1.0E-2    |
| hsa04512                    | ECM-receptor interaction pathway       | 7     | 1.9E-2    |
| hsa04010                    | MAPK signaling pathway                | 13    | 2.0E-2    |
| hsa04151                    | PI3K-Akt signaling pathway            | 16    | 2.0E-2    |

**Downregulated**

| Term                        | Function                              | Count | P-value   |
|-----------------------------|---------------------------------------|-------|-----------|
| hsa04350                    | TGF-beta signaling pathway            | 6     | 2.2E-2    |
| hsa04350                    | mRNA surveillance pathway             | 6     | 3.0E-2    |
| hsa04152                    | AMPK signaling pathway                | 7     | 3.1E-2    |
| hsa04360                    | Axon guidance pathway                 | 7     | 3.5E-2    |

Cell Counting Kit-8 migration assay

For the Cell Counting Kit-8 (CCK8) assay (Sigma, USA), HSFs (5×10^3 per well) were added to a 96-well plate, and cultured for 24, 48, or 72 h. Afterward, 20 μL of CCK-8 reagent was added into cells in serum-free medium for 2 h, followed by measurements of absorbance at 450 nm.

Statistical analysis

GraphPad Prism 8.0 was used to calculate the data, which are presented as mean±standard deviation. Paired data were compared using t tests, and 1-way analysis of variance with Tukey’s post hoc test was used to analyze data from 3 or more
groups. \( P < 0.05 \) was considered to indicate a statistically significant difference.

**Results**

**Identification of DEGs**

The gene expression profile GSE38396 was obtained from the GEO database. There were 8 samples in this microarray data, which included 4 normal individuals and 4 patients with type 2 diabetes. The 8 samples were analyzed with the Morpheus online tool, which identified 637 upregulated and 448 downregulated DEGs. The top 30 upregulated genes and top 30 downregulated genes are shown in Figure 1.

**GO and KEGG analyses**

GO analysis indicated that upregulated DEGs were significantly enriched in the following biological processes: positive regulation of GTPase activity, cardiovascular system development, positive regulation of hydrolase activity, and heart development. The downregulated DEGs were enriched in cell proliferation, reproductive structure development, reproductive system development, negative regulation of cell proliferation, and negative regulation of macromolecule metabolic processes (Table 1). With regard to cellular components, upregulated DEGs were significantly enriched in endosome lumen, axoneme part, endoplasmic reticulum lumen, vacuolar lumen, and late endosome lumen, whereas the downregulated DEGs were enriched in nucleoplasm, nucleoplasm part, adherens junction, anchoring junction, and stress fiber (Table 2). Among molecular functions, upregulated DEGs were significantly enriched in guanyl-nucleotide exchange factor activity, molecular function regulator, Ras guanyl-nucleotide exchange factor activity, inositol phosphate phosphatase activity, and pyridoxal-phosphate binding, whereas the downregulated DEGs were enriched in poly(A) RNA binding, nucleotide binding, nucleoside phosphate binding, small molecule binding, and carbohydrate derivative binding (Table 3).

![Figure 2](image-url)
The top 5 KEGG pathways of upregulated DEGs were sphingolipid metabolism pathway, estrogen signaling pathway, ECM-receptor interaction pathway, MAPK signaling pathway, and PI3K-Akt signaling pathway. The top 5 KEGG pathways of downregulated DEGs were those for Hippo signaling, TGF-beta signaling, mRNA surveillance, AMPK signaling, and axon guidance (Table 4). The results of the KEGG enrichment analysis are shown in Figure 2.

**PPI analysis**

The PPI network was obtained using STRING (https://string-db.org/cgi/input.pl) (Figure 3), and the top 10 hub genes with high degrees were then obtained using Cytoscape. The hub genes included JUN, ESR1, CD44, SMARCA4, MMP2, BMP4, GSK3B, WDR5, PTK2, and PTGS2 (Table 5). JUN had the highest degree,
### Table 5. The top 10 genes by degree of association between one node and other nodes.

| Gene ID | Gene name                                                                 | Degree | Betweenness | Closeness |
|---------|---------------------------------------------------------------------------|--------|-------------|-----------|
| JUN     | Jun proto-oncogene, AP-1 transcription factor subunit                     | 48     | 51655       | 5.18E-4   |
| ESR1    | Estrogen receptor 1                                                       | 36     | 31527       | 5.02E-4   |
| CD44    | CD44 molecule                                                             | 36     | 27941       | 4.89E-4   |
| SMARCA4 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4 | 34     | 29067       | 4.87E-4   |
| MMP2    | Matrix metallopeptidase 2                                                 | 34     | 18562       | 4.85E-4   |
| BMP4    | Bone morphogenetic protein 4                                              | 32     | 14246       | 4.63E-4   |
| GSK3B   | Glycogen synthase kinase 3 beta                                           | 29     | 22274       | 4.86E-4   |
| WDR5    | WD repeat domain 5                                                        | 29     | 21188       | 4.67E-4   |
| PTK2    | Protein tyrosine kinase 2                                                 | 29     | 22879       | 4.63E-4   |
| PTGS2   | Prostaglandin-endoperoxide synthase 2                                     | 29     | 18796       | 4.76E-4   |

**Figure 4.** (A–J) Expression boxplot of JUN, ESR1, CD44, SMARCA4, MMP2, BMP4, GSK3B, WDR5, PTK2, and PTGS2 visualized by Morpheus.
Table 6. Functional and pathway enrichment analyses of the genes in the protein–protein (PPI) network.

| Term              | Name                                      | Count | P-value   |
|-------------------|-------------------------------------------|-------|-----------|
| **A, Biological process** |                                           |       |           |
| GO: 0045597       | Positive regulation of cell differentiation | 66    | 1.7E-7    |
| GO: 0072358       | Cardiovascular system development         | 68    | 2.4E-6    |
| GO: 0072359       | Circulatory system development            | 68    | 2.4E-6    |
| **B, Cellular component** |                                           |       |           |
| GO: 0005654       | Nucleoplasm                               | 153   | 3.1E-3    |
| GO: 0005578       | Proteinaceous extracellular matrix         | 27    | 4.6E-3    |
| GO: 0097517       | Contractile actin filament bundle          | 8     | 6.7E-3    |
| **C, Molecular functions** |                                           |       |           |
| GO: 0008134       | Transcription factor binding              | 39    | 1.2E-4    |
| GO: 0005539       | Glycosaminoglycan binding                 | 20    | 5.2E-4    |
| **D, KEGG pathway** |                                           |       |           |
| hsa: 05205        | Proteoglycans in cancer pathway           | 17    | 4.8E-3    |
| hsa: 05200        | Pathways in cancer                        | 27    | 5.4E-3    |
| hsa: 04390        | Hippo signaling pathway                   | 14    | 5.8E-3    |

**Figure 5.** Degree, betweenness, and closeness of hub genes.
Figure 6. The enrichment of the top 10 genes in the protein–protein interaction (PPI) network. Biological processes: GO: 0045597, positive regulation of cell differentiation; GO: 0072358, cardiovascular system development; GO: 0072359, circulatory system development. Molecular functions: GO: 0098772, molecular function regulator; GO: 0008134, transcription factor binding; GO: 0005539, glycosaminoglycan binding. Cellular components: GO: 0005654, nucleoplasm; GO: 0005578, proteinaceous extracellular matrix; GO: 0097517, contractile actin filament bundle. KEGG pathway: hsa05205, proteoglycans in cancer pathway; hsa05200, pathways in cancer; hsa04390, Hippo signaling pathway.
Figure 7. Circular visualization of chromosomal positions and connectivity of the top 100 genes in the protein–protein interaction (PPI) network. The names of the genes are shown in the outer circle. Different colors show different values of degree, betweenness, and closeness. The outer circle represents chromosomes; lines coming from each gene point to their specific chromosomal locations. The 10 hub genes are shown in red.

at 48. The expression boxplot of hub genes is shown in Figure 4. The degree, betweenness, and closeness of the hub genes are shown in Figure 5. The GO and KEGG pathway enrichment of the genes included in the PPI network showed that these genes were related to the biological processes of positive regulation of cell differentiation, cardiovascular system development, and circulatory system development; the molecular functions of molecular function regulator, transcription factor binding, and glycosaminoglycan binding; and the cellular components nucleoplasm, proteinaceous extracellular matrix, and contractile actin filament bundle. Most of the genes were enriched in the following signaling pathways: proteoglycans in the cancer pathway, pathways in cancer, and the Hippo signaling pathway (Table 6). The enrichment of the top 10 genes is shown in Figure 6. The expression of the top 100 genes from the PPI network and their chromosomal positions are shown in Figure 7.

**ESR1 was upregulated in patients with DWs and ESR1 inhibition enhanced HSF survival in vitro**

The serum samples of the patients with DWs and the healthy controls were collected and quantitative real-time...
reverse-transcription polymerase chain reaction (qRT-PCR) analyses were performed to quantify ESR1 expression in these samples. As shown in Figure 8A, ESR1 was significantly upregulated in DW patients, which is consistent with the bioinformatic results. The effect of ESR1 on the proliferation of HSFs was then investigated in vitro. The CCK-8 assay showed that ESR1 inhibition promoted HSF proliferation (Figure 8B, 8C). Similarly, the qRT-PCR results indicated that the proliferation-related genes were increased and the apoptosis-related genes were decreased after ESR1 knockdown treatment (Figure 8D, 8E).

**Discussion**

Many studies have focused on the mechanisms underlying DWs, and the identification of the key genes involved in DW development is a crucial step in these investigations [15]. In the present study, we screened for key genes associated with DW development, using mRNA expression datasets from DW and control patients. This analysis led to the identification of JUN, MMP2, and ESR1 as potential key genes in diabetes; among these, JUN, MMP2, and ESR1 were upregulated. To explore whether these 3 genes were similarly enriched in patients with DWs, we carried out qRT-PCR analyses, which indicated that JUN, MMP2, and ESR1 were significantly enriched in serum samples from the patients. Therefore, we hypothesized that JUN, ESR1, and MMP2 are critical regulatory genes of DWs.

JUN is a protein coding gene, and diseases associated with JUN include pertussis and sarcoma [16]. Among its related pathways are the oxytocin signaling pathway and the CCR5 pathway in macrophages [17]. GO annotations related to this gene include sequence-specific DNA binding [18]. A recent study reported that the c-Jun/INK/p53 signaling pathway is involved in the regulation of cardiac remodeling and apoptosis induced by myocardial infarction [19]. In the present study, we found that JUN is significantly upregulated in the diabetes based on the bioinformatic method, and it could be a key gene in DW development.

Matrix metalloprotein 2 (MMP2) has been reported to be involved in diverse functions, such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture [20]. MMP2 was previously extensively studied in the context of wound healing and diabetes. Its role in DWs is likely multifaceted, involving tissue remodeling and matrix degradation.

ESR1, another protein coding gene, is involved in several biological processes, including response to estrogen and regulation of cell cycle. In the context of DWs, the upregulation of ESR1 suggests its potential role in the proliferative and angiogenic responses associated with wound healing. Further investigation into the mechanisms by which ESR1 contributes to DW development is warranted.

The results from these qRT-PCR analyses provide a foundation for future studies aimed at understanding the regulatory mechanisms underlying DWs. By identifying key genes like JUN, MMP2, and ESR1, researchers can develop targeted therapies to mitigate the clinical impact of DWs.
demonstrated to be involved in the regulation of wound healing, and the upregulation of MMP2 was reported to accelerate cutaneous wound healing via enhancing the functionality of keratinocytes [21]. Interestingly, MMP2 was also demonstrated to be associated with the development of diabetes [22]. In the present study, MMP2 was found to be upregulated in diabetes, which is consistent with a prior study [23]. Thus, we regard MMP2 as another potential key gene in DW development.

Estrogen receptor 1 (ESR1) is a type of nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1, and Sp3, to mediate estrogen response element-independent signaling [24]. A prior study reported that ESR1 was related to the molecular mechanisms of astragalan membranes for treating type 2 diabetes mellitus [25]. Fibroblasts are the key cells in cutaneous wound repair, and their proper function is essential for wound contraction, collagen synthesis, and tissue remodeling. Therefore, we investigated how inhibition of ESR1 affects fibroblast function in vitro. We found that ESR1 is enriched in diabetes, and the qRT-PCR results indicated that ESR1 is also enriched in patients with DWS. In addition, inhibition of ESR1 was further demonstrated as useful for HSF survival. Considering our results, together with a recent study that demonstrated the effect of ESR1 in wound healing [26], we regard ESR1 as a key gene in the regulation of DW healing.

Conclusions

In summary, the present study suggests that ESR1 is a critical gene in the regulation of DW healing, which introduces potential therapeutic targets for DW healing. Although bioinformatics analysis and basic experimental tools were used to identify underlying crucial biomarkers of DW, the current study did not demonstrate the sensitivity and specificity of the key genes identified. However, from the bioinformatic and the cell-based analysis results, we assume that ESR1 exerts a regulatory effect on DW healing via affecting the survival of fibroblasts.

References:

1. Argiana V, Kanellos PT, Eleftheriadou I et al: Low-glycemic-index/load desserts decrease glycemic and insulimic response in patients with type 2 diabetes mellitus. Nutrients, 2020; 12(7): 2153
2. Xu Y, Cao K, Guo B et al: Lowered levels of nicotinic acetylcholine receptors and elevated apoptosis in the hippocampus of brains from patients with type 2 diabetes mellitus and db/db mice. Aging (Albany NY), 2020; 12(14): 14205–18
3. Pratley R, Daggo-Jack S, Charbonnel B et al: Efficacy and safety of ertugliflozin in older patients with type 2 diabetes mellitus: A pooled analysis of phase III studies. Diabetes Obes Metab, 2020 [Online ahead of print]
4. Xiong Y, Chen L, Yan C et al: Circulating exosomal miR-20b-5p inhibition re-stores Wnt/β signaling and reverses diabetes-associated impaired wound healing. Small, 2020; 16(3): e1904044
5. Xiong Y, Chen L, Yu T et al: Inhibition of circulating exosomal microRNA-15a-3p accelerates diabetic wound repair. Aging (Albany NY), 2020; (12): 8968–86
6. Mi B, Chen L, Xiong Y et al: Saliva exosomes-derived UBE2O mRNA promotes angiogenesis in cutaneous wounds by targeting SMAD6. J Nanobiotechnology, 2020; 18(1): 68
7. Davis FM, denDekker A, Joshi AD et al: Palmitate-TLR4 signaling regulates diabetic wound healing, and the upregulation of MMP2 was reported to accelerate wound contraction, collagen synthesis, and tissue remodeling.